<DOC>
	<DOCNO>NCT00352235</DOCNO>
	<brief_summary>Phase I/II trial KRN7000 patient chronic hepatitis C. Study objective : To evaluate compare safety tolerability 3 ascend dos a-GalCer . The primary efficacy parameter : HCV-RNA response end treatment . Secondary efficacy parameter : Serum ALT response . Further objectives study evaluate effect a-GalCer serum cytokine IFNg TNFa iNKT cell . Number dose level : 3 Investigational product : KRN7000 Route administration : intravenous Dosages frequency : 0.1 , 1 , 10 mcg/kg , monthly injection , 3 time ( day 0 , day 28 day 56 )</brief_summary>
	<brief_title>Phase I/II Trial KRN7000 Patients With Chronic Hepatitis C Infection</brief_title>
	<detailed_description>Phase I/II trial KRN7000 patient chronic hepatitis C. This study multicenter double-blind randomized placebo-controlled phase I/II dose-escalation trial . The protocol conduct The Netherlands , Belgium Germany . Patients chronic hepatitis C meet inclusion criterion assign receive a-GalCer ( KRN7000 ( ( 2S , 3S , 4R ) -1-O- ( a-D-galactopyranosyl ) -N-hexacosanoyl-2-amino-1,3,4-octadecanetriol ) , Kirin Pharmaceutical Co. , Ltd. , Gunma , Japan ) placebo intravenously , thrice interval 4 week . Cohorts 12 patient enter three dose level ( 0.1 , 1 10 mg/kg body weight ) . Three patient per dose level randomize placebo arm . Dose escalation next cohort decide evaluation safety review board safety data collect patient complete 3 week first injection precede dose cohort . After completion 8 week treatment , injection 0 , 4 8 week , patient monitor without therapy additional 16 week . Study objectives : The objective study evaluate compare safety tolerability 3 ascend dos a-GalCer . The primary efficacy parameter response end treatment , base serum hepatitis C virus ribonucleic acid ( HCV RNA ) level . As secondary efficacy parameter serum ALT level evaluate . Further objective study evaluate effect a-GalCer serum cytokine IFNg TNFa iNKT cell .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>KRN 7000</mesh_term>
	<criteria>Chronic hepatitis C Liver biopsy within 3 year entry study HCV RNA &gt; 10000 copies/mL Age 1870 year ALT &gt; 1.2 time ULN write informed consent Adequate contraception Cirrhosis Decompensated liver disease ALT &gt; 10 time ULN Pregnancy Major illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>KRN7000</keyword>
	<keyword>a-GalCer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>Natural Killer T cell</keyword>
	<keyword>interferon</keyword>
</DOC>